Uddannelses- og Forskningsministeriet - Innovationsfonden - Eurostars-projekt SaferBI-OPHAMA

Project: Research

Project Details


Host cell protein impurities in biopharmaceuticals may cause severe side effects. Today´s commercial ELISA can generally only monitor 30-70% of the host cell proteins in a drug sample, and provide no information about identity
of these host cell proteins. We will deliver an innovative analysis service, enabling identification and relative quantification of individual host cell proteins, and selection of 2-3 commercial ELISA that in combination can monitor all host cell proteins in a drug sample.
Effective start/end date01/04/201731/05/2019